Literature DB >> 12075005

Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development.

Li Fan1, Louise R Simard.   

Abstract

Childhood spinal muscular atrophy (SMA) is a common neuromuscular disorder caused by absent or deficient full-length survival motor neuron (SMN) protein. Clinical studies and animal models suggest that SMA is a developmental defect in neuromuscular interaction; however, the role of SMN in this process remains unclear. In the present study, we have determined the subcellular localization of SMN during retinoic-acid-induced neuronal differentiation of mouse embryonal teratocarcinoma P19 cells as well as in skeletal muscle during the critical period of neuromuscular maturation. We demonstrate, for the first time, SMN accumulation in growth-cone- and filopodia-like structures in both neuronal- and glial-like cells, identifying SMN as a new growth cone marker. Indeed, SMN was present at the leading edge of neurite outgrowths, suggesting that SMN may play a role in this process. In addition, SMN was detected as small dot-like particles within the cytoplasm of skeletal muscle during the first 2 weeks after birth, but their number peaked by P6. Intense SMN staining in neuromuscular junctions was observed throughout the entire postnatal period examined. Taken together, these results suggest that SMN may indeed fulfill neuronal- and muscle-specific functions, providing a more plausible mechanism explaining motor neuron degeneration and associated denervation atrophy of skeletal muscles in SMA. The primary SMA pathology most likely initiates in the peripheral axon--the result of deficient neurite outgrowth and/or neuromuscular maturation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075005     DOI: 10.1093/hmg/11.14.1605

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  55 in total

Review 1.  Motoneuron injury and repair: New perspectives on gonadal steroids as neurotherapeutics.

Authors:  Julie E Tetzlaff; Christopher B Huppenbauer; Lisa Tanzer; Thomas D Alexander; Kathryn J Jones
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Alpha-synuclein loss in spinal muscular atrophy.

Authors:  Gyula Acsadi; Xingli Li; Kelley J Murphy; Kathryn J Swoboda; Graham C Parker
Journal:  J Mol Neurosci       Date:  2010-07-17       Impact factor: 3.444

3.  RNA splicing capability of live neuronal dendrites.

Authors:  J Glanzer; K Y Miyashiro; J-Y Sul; L Barrett; B Belt; P Haydon; J Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

Review 4.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 5.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

6.  Compensatory axon sprouting for very slow axonal die-back in a transgenic model of spinal muscular atrophy type III.

Authors:  Esther Udina; Charles T Putman; Luke R Harris; Neil Tyreman; Victoria E Cook; Tessa Gordon
Journal:  J Physiol       Date:  2017-01-25       Impact factor: 5.182

7.  Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy.

Authors:  Zhi-Bo Wang; Xiaoqing Zhang; Xue-Jun Li
Journal:  Cell Res       Date:  2012-12-04       Impact factor: 25.617

Review 8.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

9.  SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain.

Authors:  Michael P Walker; T K Rajendra; Luciano Saieva; Jennifer L Fuentes; Livio Pellizzoni; A Gregory Matera
Journal:  Hum Mol Genet       Date:  2008-08-08       Impact factor: 6.150

10.  Evaluation of splicing efficiency in lymphoblastoid cell lines from patients with splicing-factor retinitis pigmentosa.

Authors:  Lenka Ivings; Katherine V Towns; M A Matin; Charles Taylor; Frederique Ponchel; Richard J Grainger; Rajkumar S Ramesar; David A Mackey; Chris F Inglehearn
Journal:  Mol Vis       Date:  2008-12-18       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.